A Novel, Multi-Target Natural Drug Candidate, Matrine, Improves Cognitive Deficits in Alzheimer’s Disease Transgenic Mice by Inhibiting Aβ Aggregation and Blocking the RAGE/Aβ Axis

Molecular Neurobiology

Volumn 54, Issue 3, 2017, Pages 1939-1952

  Cui, Lili ^a   Cai, Yujie ^a   Cheng, Wanwen ^a   Liu, Gen ^a   Zhao, Jianghao ^a   Cao, Hao ^b   Tao, Hua ^a   Wang, Yan ^a   Yin, Mingkang ^a   Liu, Tingting ^a   Liu, Yu ^a   Huang, Pengru ^a   Liu, Zhou ^a   Li, Keshen ^a,c   Zhao, Bin ^a  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^c JINAN UNIVERSITY   (China)

Author keywords

Alzheimer s disease; Matrine; Receptors for Advanced glycation end product; Amyloid peptide

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; MATRINE; OLIGOMER; TUMOR NECROSIS FACTOR; AGER PROTEIN, MOUSE; ALKALOID; AMYLOID BETA-PROTEIN (1-42); HERBACEOUS AGENT; PEPTIDE FRAGMENT; QUINOLIZINE DERIVATIVE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; COGNITIVE DEFECT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SCREENING; DRUG TARGETING; FEASIBILITY STUDY; GENE EXPRESSION REGULATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MOLECULAR DOCKING; MORRIS WATER MAZE TEST; MOUSE; NONHUMAN; PROTEIN AGGREGATION; PROTEIN EXPRESSION; RECEPTOR BLOCKING; SENILE PLAQUE; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TREATMENT DURATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CELL SURVIVAL; DRUG DELIVERY SYSTEM; DRUG EFFECTS; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROCEDURES; PROTEINOSIS; TUMOR CELL LINE;

ALKALOIDS; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; COGNITIVE DYSFUNCTION; DRUG DELIVERY SYSTEMS; DRUGS, CHINESE HERBAL; HUMANS; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; PROTEIN AGGREGATION, PATHOLOGICAL; QUINOLIZINES; RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS;

EID: 84959141396     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-016-9783-8     Document Type: Article

References (68)

1. Alcolea D, Martinez-Lage P, Sanchez-Juan P, Olazaran J, Antunez C, Izagirre A, Ecay-Torres M, Estanga A et al (2015) Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease. Neurology 85(7):626–633. doi:10.1212/WNL.0000000000001859
2. Dal Pra I, Chiarini A, Pacchiana R, Chakravarthy B, Whitfield JF, Armato U (2008) Emerging concepts of how beta-amyloid proteins and pro-inflammatory cytokines might collaborate to produce an ‘Alzheimer brain’ (Review). Mol Med Rep 1(2):173–178
3. Bloom GS (2014) Amyloid-beta and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol 71(4):505–508. doi:10.1001/jamaneurol.2013.5847
4. Chetelat G (2013) Alzheimer disease: Abeta-independent processes-rethinking preclinical AD. Nat Rev Neurol 9(3):123–124. doi:10.1038/nrneurol.2013.21
5. Nixon RA (2014) Alzheimer neurodegeneration, autophagy, and Abeta secretion: the ins and outs (comment on DOI 10.1002/bies.201400002). Bioessays 36(6):547. doi:10.1002/bies.201400064
6. Clarke JR, Lyra ESNM, Figueiredo CP, Frozza RL, Ledo JH, Beckman D, Katashima CK, Razolli D et al (2015) Alzheimer-associated Abeta oligomers impact the central nervous system to induce peripheral metabolic deregulation. EMBO Mol Med 7(2):190–210. doi:10.15252/emmm.201404183
7. Cheng IH, Scearce-Levie K, Legleiter J, Palop JJ, Gerstein H, Bien-Ly N, Puolivali J, Lesne S et al (2007) Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem 282(33):23818–23828. doi:10.1074/jbc.M701078200
8. Yu X, Wang Q, Pan Q, Zhou F, Zheng J (2013) Molecular interactions of Alzheimer amyloid-beta oligomers with neutral and negatively charged lipid bilayers. Phys Chem Chem Phys 15(23):8878–8889. doi:10.1039/c3cp44448a
9. Morohashi Y, Tomita T, Iwatsubo T (2010) Molecular targeted therapy in Alzheimer disease. Nihon Rinsho 68(10):1906–1910
10. Miners JS, Barua N, Kehoe PG, Gill S, Love S (2011) Abeta-degrading enzymes: potential for treatment of Alzheimer disease. J Neuropathol Exp Neurol 70(11):944–959. doi:10.1097/NEN.0b013e3182345e46
11. Lemere CA, Maier M, Jiang L, Peng Y, Seabrook TJ (2006) Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: lessons from mice, monkeys, and humans. Rejuvenation Res 9(1):77–84. doi:10.1089/rej.2006.9.77
12. Estrada LD, Soto C (2007) Disrupting beta-amyloid aggregation for Alzheimer disease treatment. Curr Top Med Chem 7(1):115–126
13. Fang L, Gou S, Liu X, Cao F, Cheng L (2014) Design, synthesis and anti-Alzheimer properties of dimethylaminomethyl-substituted curcumin derivatives. Bioorg Med Chem Lett 24(1):40–43. doi:10.1016/j.bmcl.2013.12.011
14. Garcia-Alloza M, Borrelli LA, Rozkalne A, Hyman BT, Bacskai BJ (2007) Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J Neurochem 102(4):1095–1104. doi:10.1111/j.1471-4159.2007.04613.x
15. McKoy AF, Chen J, Schupbach T, Hecht MH (2012) A novel inhibitor of amyloid beta (Abeta) peptide aggregation: from high throughput screening to efficacy in an animal model of Alzheimer disease. J Biol Chem 287(46):38992–39000. doi:10.1074/jbc.M112.348037
16. Lai AY, McLaurin J (2012) Inhibition of amyloid-beta peptide aggregation rescues the autophagic deficits in the TgCRND8 mouse model of Alzheimer disease. Biochim Biophys Acta 1822(10):1629–1637. doi:10.1016/j.bbadis.2012.07.003
17. Hamada Y, Miyamoto N, Kiso Y (2015) Novel beta-amyloid aggregation inhibitors possessing a turn mimic. Bioorg Med Chem Lett 25(7):1572–1576. doi:10.1016/j.bmcl.2015.02.016
18. Peters C, Fernandez-Perez EJ, Burgos CF, Espinoza MP, Castillo C, Urrutia JC, Streltsov VA, Opazo C et al (2013) Inhibition of amyloid beta-induced synaptotoxicity by a pentapeptide derived from the glycine zipper region of the neurotoxic peptide. Neurobiol Aging 34(12):2805–2814. doi:10.1016/j.neurobiolaging.2013.06.001
19. Jiang P, Li W, Shea JE, Mu Y (2011) Resveratrol inhibits the formation of multiple-layered beta-sheet oligomers of the human islet amyloid polypeptide segment 22-27. Biophys J 100(6):1550–1558. doi:10.1016/j.bpj.2011.02.010
20. Fukumoto H, Takahashi H, Tarui N, Matsui J, Tomita T, Hirode M, Sagayama M, Maeda R et al (2010) A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer’s disease. J Neurosci 30(33):11157–11166. doi:10.1523/JNEUROSCI.2884-10.2010
21. Huang HJ, Lee CC, Chen CY (2014) In silico design of BACE1 inhibitor for Alzheimer’s disease by traditional Chinese medicine. Biomed Res Int 2014:741703. doi:10.1155/2014/741703
22. Cheng X, Zhou Y, Gu W, Wu J, Nie A, Cheng J, Zhou J, Zhou W et al (2013) The selective BACE1 inhibitor VIa reduces amyloid-beta production in cell and mouse models of Alzheimer’s disease. J Alzheimers Dis 37(4):823–834. doi:10.3233/JAD-130836
23. Meunier J, Villard V, Givalois L, Maurice T (2013) The gamma-secretase inhibitor 2-[(1R)-1-[(4-chlorophenyl)sulfonyl](2,5-difluorophenyl) amino]ethyl-5-fluorobenzenebutanoic acid (BMS-299897) alleviates Abeta1-42 seeding and short-term memory deficits in the Abeta25-35 mouse model of Alzheimer’s disease. Eur J Pharmacol 698(1-3):193–199. doi:10.1016/j.ejphar.2012.10.033
24. Mori T, Rezai-Zadeh K, Koyama N, Arendash GW, Yamaguchi H, Kakuda N, Horikoshi-Sakuraba Y, Tan J et al (2012) Tannic acid is a natural beta-secretase inhibitor that prevents cognitive impairment and mitigates Alzheimer-like pathology in transgenic mice. J Biol Chem 287(9):6912–6927. doi:10.1074/jbc.M111.294025
25. Rafii MS, Aisen PS (2015) Advances in Alzheimer’s disease drug development. BMC Med 13:62. doi:10.1186/s12916-015-0297-4
26. Liu H, Wang L, Su W, Xie XQ (2014) Advances in recent patent and clinical trial drug development for Alzheimer’s disease. Pharm Pat Anal 3(4):429–447. doi:10.4155/ppa.14.22
27. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L et al (1996) RAGE and amyloid-beta peptide neurotoxicity in Alzheimer’s disease. Nature 382(6593):685–691. doi:10.1038/382685a0
28. Schmidt AM, Sahagan B, Nelson RB, Selmer J, Rothlein R, Bell JM (2009) The role of RAGE in amyloid-beta peptide-mediated pathology in Alzheimer’s disease. Curr Opin Investig Drugs 10(7):672–680
29. Guglielmotto M, Aragno M, Tamagno E, Vercellinatto I, Visentin S, Medana C, Catalano MG, Smith MA et al (2012) AGEs/RAGE complex upregulates BACE1 via NF-kappaB pathway activation. Neurobiol Aging 33(1):196. doi:10.1016/j.neurobiolaging.2010.05.026
30. Cho HJ, Son SM, Jin SM, Hong HS, Shin DH, Kim SJ, Huh K, Mook-Jung I (2009) RAGE regulates BACE1 and Abeta generation via NFAT1 activation in Alzheimer’s disease animal model. FASEB J 23(8):2639–2649. doi:10.1096/fj.08-126383
31. Miller MC, Tavares R, Johanson CE, Hovanesian V, Donahue JE, Gonzalez L, Silverberg GD, Stopa EG (2008) Hippocampal RAGE immunoreactivity in early and advanced Alzheimer’s disease. Brain Res 1230:273–280. doi:10.1016/j.brainres.2008.06.124
32. Slowik A, Merres J, Elfgen A, Jansen S, Mohr F, Wruck CJ, Pufe T, Brandenburg LO (2012) Involvement of formyl peptide receptors in receptor for advanced glycation end products (RAGE)--and amyloid beta 1-42-induced signal transduction in glial cells. Mol Neurodegener 7:55. doi:10.1186/1750-1326-7-55
33. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L et al (2003) RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9(7):907–913. doi:10.1038/nm890
34. Perrone L, Sbai O, Nawroth PP, Bierhaus A (2012) The complexity of sporadic Alzheimer’s Disease pathogenesis: the role of RAGE as therapeutic target to promote neuroprotection by inhibiting neurovascular dysfunction. Int J Alzheimers Dis 2012:734956. doi:10.1155/2012/734956
35. Galasko D, Bell J, Mancuso JY, Kupiec JW, Sabbagh MN, van Dyck C, Thomas RG, Aisen PS (2014) Clinical trial of an inhibitor of RAGE-Abeta interactions in Alzheimer disease. Neurology 82(17):1536–1542. doi:10.1212/WNL.0000000000000364
36. Deane R, Singh I, Sagare AP, Bell RD, Ross NT, LaRue B, Love R, Perry S et al (2012) A multimodal RAGE-specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest 122(4):1377–1392. doi:10.1172/JCI58642
37. Sabbagh MN, Agro A, Bell J, Aisen PS, Schweizer E, Galasko D (2011) PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease. Alzheimer Dis Assoc Disord 25(3):206–212. doi:10.1097/WAD.0b013e318204b550
38. Matrone C, Djelloul M, Taglialatela G, Perrone L (2015) Inflammatory risk factors and pathologies promoting Alzheimer’s disease progression: is RAGE the key? Histol Histopathol 30(2):125–139, HH-11-519
39. Viayna E, Sabate R, Munoz-Torrero D (2013) Dual inhibitors of beta-amyloid aggregation and acetylcholinesterase as multi-target anti-Alzheimer drug candidates. Curr Top Med Chem 13(15):1820–1842, 54933
40. Sivilia S, Lorenzini L, Giuliani A, Gusciglio M, Fernandez M, Baldassarro VA, Mangano C, Ferraro L et al (2013) Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice. BMC Neurosci 14:44. doi:10.1186/1471-2202-14-44
41. Parker JL, Newstead S (2014) Molecular basis of nitrate uptake by the plant nitrate transporter NRT1.1. Nature 507(7490):68–72. doi:10.1038/nature13116
42. Xiong X, Coombs PJ, Martin SR, Liu J, Xiao H, McCauley JW, Locher K, Walker PA et al (2013) Receptor binding by a ferret-transmissible H5 avian influenza virus. Nature 497(7449):392–396. doi:10.1038/nature12144
43. Cao H, Gao G, Gu Y, Zhang J, Zhang Y (2014) Trp358 is a key residue for the multiple catalytic activities of multifunctional amylase OPMA-N from Bacillus sp. ZW2531-1. Appl Microbiol Biotechnol 98(5):2101–2111. doi:10.1007/s00253-013-5085-5
44. Cui L, Zhang Y, Cao H, Wang Y, Teng T, Ma G, Li Y, Li K (2013) Ferulic acid inhibits the transition of amyloid-beta42 monomers to oligomers but accelerates the transition from oligomers to fibrils. J Alzheimers Dis 37(1):19–28. doi:10.3233/JAD-130164
45. Chaney MO, Stine WB, Kokjohn TA, Kuo YM, Esh C, Rahman A, Luehrs DC, Schmidt AM et al (2005) RAGE and amyloid beta interactions: atomic force microscopy and molecular modeling. Biochim Biophys Acta 1741(1-2):199–205. doi:10.1016/j.bbadis.2005.03.014
46. Park H, Adsit FG, Boyington JC (2010) The 1.5 A crystal structure of human receptor for advanced glycation endproducts (RAGE) ectodomains reveals unique features determining ligand binding. J Biol Chem 285(52):40762–40770. doi:10.1074/jbc.M110.169276
47. De Strooper B (2014) Lessons from a failed gamma-secretase Alzheimer trial. Cell 159(4):721–726. doi:10.1016/j.cell.2014.10.016
48. Tang J, Ghosh A (2011) Treating transgenic Alzheimer mice with a beta-secretase inhibitor, what have we learned? Aging (Albany NY) 3(1):14–16, 100267
49. Ziani-Cherif C, Mostefa-Kara B, Brixi-Gormat FZ (2006) Gamma-secretase as a pharmacological target in Alzheimer disease research: when, why and how? Curr Pharm Des 12(33):4313–4335
50. Deane RJ (2012) Is RAGE still a therapeutic target for Alzheimer’s disease? Future Med Chem 4(7):915–925. doi:10.4155/fmc.12.51
51. McKoy AF, Chen J, Schupbach T, Hecht MH (2014) Structure-activity relationships for a series of compounds that inhibit aggregation of the Alzheimer’s peptide, Abeta42. Chem Biol Drug Des 84(5):505–512. doi:10.1111/cbdd.12341
52. Ahmed M, Davis J, Aucoin D, Sato T, Ahuja S, Aimoto S, Elliott JI, Van Nostrand WE et al (2010) Structural conversion of neurotoxic amyloid-beta(1-42) oligomers to fibrils. Nat Struct Mol Biol 17(5):561–567. doi:10.1038/nsmb.1799
53. Naldi M, Fiori J, Pistolozzi M, Drake AF, Bertucci C, Wu R, Mlynarczyk K, Filipek S et al (2012) Amyloid beta-peptide 25-35 self-assembly and its inhibition: a model undecapeptide system to gain atomistic and secondary structure details of the Alzheimer’s disease process and treatment. ACS Chem Neurosci 3(11):952–962. doi:10.1021/cn3000982
54. Davis CH, Berkowitz ML (2009) Structure of the amyloid-beta (1-42) monomer absorbed to model phospholipid bilayers: a molecular dynamics study. J Phys Chem B 113(43):14480–14486. doi:10.1021/jp905889z
55. Schneider LS, Mangialasche F, Andreasen N, Feldman H, Giacobini E, Jones R, Mantua V, Mecocci P et al (2014) Clinical trials and late-stage drug development for Alzheimer’s disease: an appraisal from 1984 to 2014. J Intern Med 275(3):251–283. doi:10.1111/joim.12191
56. Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M (2010) Alzheimer’s disease: clinical trials and drug development. Lancet Neurol 9(7):702–716. doi:10.1016/S1474-4422(10)70119-8
57. Chen X, Walker DG, Schmidt AM, Arancio O, Lue LF, Yan SD (2007) RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer’s disease. Curr Mol Med 7(8):735–742
58. Yan SD, Stern D, Kane MD, Kuo YM, Lampert HC, Roher AE (1998) RAGE-Abeta interactions in the pathophysiology of Alzheimer’s disease. Restor Neurol Neurosci 12(2-3):167–173
59. Yan SS, Chen D, Yan S, Guo L, Du H, Chen JX (2012) RAGE is a key cellular target for Abeta-induced perturbation in Alzheimer’s disease. Front Biosci (Schol Ed) 4:240–250, 265
60. Fang F, Lue LF, Yan S, Xu H, Luddy JS, Chen D, Walker DG, Stern DM et al (2010) RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer’s disease. FASEB J 24(4):1043–1055. doi:10.1096/fj.09-139634
61. Onyango IG, Tuttle JB, Bennett JP Jr (2005) Altered intracellular signaling and reduced viability of Alzheimer’s disease neuronal cybrids is reproduced by beta-amyloid peptide acting through receptor for advanced glycation end products (RAGE). Mol Cell Neurosci 29(2):333–343. doi:10.1016/j.mcn.2005.02.012
62. Takuma K, Fang F, Zhang W, Yan S, Fukuzaki E, Du H, Sosunov A, McKhann G et al (2009) RAGE-mediated signaling contributes to intraneuronal transport of amyloid-beta and neuronal dysfunction. Proc Natl Acad Sci U S A 106(47):20021–20026. doi:10.1073/pnas.0905686106
63. Yan SF, Ramasamy R, Schmidt AM (2010) Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochem Pharmacol 79(10):1379–1386. doi:10.1016/j.bcp.2010.01.013
64. Kan QC, Lv P, Zhang XJ, Xu YM, Zhang GX, Zhu L (2015) Matrine protects neuro-axon from CNS inflammation-induced injury. Exp Mol Pathol 98(1):124–130. doi:10.1016/j.yexmp.2015.01.001
65. Chuang CY, Xiao JG, Chiou GC (1987) Ocular anti-inflammatory actions of matrine. J Ocul Pharmacol 3(2):129–134
66. Zhang B, Liu ZY, Li YY, Luo Y, Liu ML, Dong HY, Wang YX, Liu Y et al (2011) Antiinflammatory effects of matrine in LPS-induced acute lung injury in mice. Eur J Pharm Sci 44(5):573–579. doi:10.1016/j.ejps.2011.09.020
67. Liu N, Kan QC, Zhang XJ, Xv YM, Zhang S, Zhang GX, Zhu L (2014) Upregulation of immunomodulatory molecules by matrine treatment in experimental autoimmune encephalomyelitis. Exp Mol Pathol 97(3):470–476. doi:10.1016/j.yexmp.2014.10.004
68. Suo Z, Liu Y, Ferreri M, Zhang T, Liu Z, Mu X, Han B (2009) Impact of matrine on inflammation related factors in rat intestinal microvascular endothelial cells. J Ethnopharmacol 125(3):404–409. doi:10.1016/j.jep.2009.07.023